Expansion of ResidenceTimer™ kinase panel
Determination of target residence time may help you to differentiate your drug candidate from competitor compounds. Drugs that reside on their target for several hours will have the advantage that their pharmacodynamic effect [...]
Compound profiling on EGFR mutants and osimertinib-resistant cell lines
Mutations in the epidermal growth factor receptor (EGFR) are the most common oncogenic drivers in non-small cell lung cancer (NSCLC), but many patients treated with EGFR kinase inhibitors develop drug resistance. At Oncolines, [...]
Cancer cell panel profiling of MAPK pathway inhibitors
The MAPK signal transduction pathway plays a key role in tumor progression. Mutations in the corresponding driver genes, such as KRAS and BRAF, are oncogenic drivers in several malignancies. Tumors driven by V600-mutated [...]
Compound profiling in PARP inhibitor-resistant cancer cell lines
Drug resistance is a major problem in the treatment of cancer. Many aspects of clinical drug resistance can be studied in drug-resistant cell lines generated in vitro. At Oncolines, there are more than [...]
Oncolines contributes to publication in Mucosal Immunology
Biacore studies prove binding of bacterial lysate OM-85 to Toll-like receptors OM-85, also known as Broncho-Vaxom®, is an extract of more than 21 different respiratory pathogenic bacterial strains that is indicated for the prevention [...]
Oncolines contributes to publication inNature Communications
Identification of first-in-class, potent and selective CK1α degrader In a new study, which was published today in Nature Communications, investigators from St. Jude Children’s Research Hospital describe the discovery and characterization of a [...]
New bioinformatics service
Oncolines launches ProteomicsProfiler Figure (A) Scatterplots of basal gene and protein expression levels for EGFR (left, strongly correlated) and KDR (right, not correlated) in cancer cell lines. (B) Boxplot of Pearson correlations [...]
Oncolines presentation at Revvity Symposium Ghent
Biomarkers for Patient Stratification and Target Engagement Dr. Guido Zaman, Managing Director of Oncolines B.V., will present at the Revvity North Symposium Life Science & Applied Genomics 2023, which will take place [...]
Booth #410 – Oncolines at AACR-NCI-EORTC 2023 in Boston
Molecular Targets and Cancer Therapeutics conference Oncolines will present two posters at the Molecular Targets and Cancer Therapeutics conference in Boston next week. Oncolines will also exhibit in the Exhibition Area (Booth [...]
100 years pharmaceutical industry in Oss
Oncolines team featured in ‘Walk of Fame’
To celebrate the past and future of pharma industry in Oss, a Walk of Fame was opened at the Pivot Park, the biopharmaceutical campus of Oss and home of Oncolines. The Walk of Fame showcases [...]
New case study on Oncolines® website
Target identification of hits from a phenotypic screen Phenotypic screens measure a desired biological effect in a disease-relevant cellular context. In contrast to target-based assays, phenotypic screens are agnostic of a defined molecular [...]
New publication in Cancer Chemotherapy and Pharmacology
Comparative biochemical kinase profiling of VEGFR2 inhibitors Figure. Radar plot showing residual activity of 270 kinases in the presence of rivoceranib (160 or 1600 nM) or 1000 nM of 10 FDA-approved reference [...]
Oncolines Hosts Webinar: Biomarkers for Patient Stratification & Target Engagement
Despite significant advances made in the treatment of cancer through the past decades, many new therapeutic entities fail in the clinical research phase. To accelerate your drug development process and improve patient treatment, the [...]
New Oncolines publication in Cancers
IL4I1 in ascites as a marker in high-grade serous ovarian cancer The emergence of immunotherapy has revolutionized cancer treatment for various malignancies. However, immunotherapies have demonstrated only limited efficacy in ovarian cancer, [...]
Oncolines Team Joins Symeres
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities Nijmegen, the Netherlands: Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), [...]
New in Frontiers in Oncology: comparative profiling study of newly approved kinase inhibitors
In the last two decades, nearly 60 small molecule kinase inhibitors have been approved by the FDA for oncology indications. Although the human kinome consists of around 500 kinases, the inhibitors that are [...]
On-demand webinar on cancer genomics
Cancer genomics is key to Oncolines’ cancer cell line profiling services and bioinformatics. In PIVOTTalk, a webinar series hosted by the Pivot Park, Jeffrey Kooijman and Tessa de Bitter describe the history [...]
Oncolines Hosts Webinar: How to Select the Best Platform for Testing Drug Combinations
Many cancer treatments are combination therapies. Combining drugs can improve therapy response, prevent drug resistance, or reduce toxicity. This June, Oncolines hosted a webinar discussing the different approaches available to identify new synergistic drug combinations [...]
Case study – Gene expression profiling to understand and combat drug resistance
RNA sequencing provides insight into the mechanism of kinase inhibitor resistance Figure: Gene set enrichment analysis indicated Myc target genes were upregulated in the resistant clone Clinical response to [...]
Proposed new combination treatment strategy for pediatric ALL published in Nature Communication
Oncolines contributes to a proposed new combination treatment strategy for pediatric acute lymphoblastic leukemia published in Nature Communication T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from aberrant proliferation of T [...]
Oncolines News Flash
First presentation of novel mitotic checkpoint inhibitor BAL0891 data at ESMO TAT congress 2022 At the virtual Targeted Anticancer Therapy (TAT) congress, which was organized by the European Society of Medical Oncology (ESMO) [...]
Oncolines News Flash
Oncolines to present detailed profiling of recently approved kinase inhibitors at the ESMO TAT Currently approved small molecule kinase inhibitors act only through a limited number of kinase targets. Well-known targets are EGFR, [...]
Oncolines News Flash
OncolinesProfiler™ Compound Library is approaching the 200 mark. Clustering analysis via OncolinesProfiler™ compares your compound’s IC50 fingerprint against the cellular activity of other anti-cancer therapeutics. The OncolinesProfiler™ compound library started out as a [...]
Case study: Combination matrix to determine Bliss independence synergy scores
November 19, 2021: A new case study is presented, in which the use of a combination matrix for the determination of synergy is highlighted. The figure shows the combination of the [...]
Oncolines opens a new screening lab
Oncolines is expanding its lab capacity with a new screening lab including cell culture facilities. Oncolines opens a new screening lab Oncolines is expanding its lab [...]
NTRC Precision Medicine Services is now Oncolines
As an independent company, Oncolines will now be singularly focused on offering the best precision medicine services in oncology and cancer immunotherapy for our clients. Our Oncolines™ cancer cell line panels can identify drug [...]
[Webinar] Comparative Cancer Cell Panel Profiling of Recently Approved Kinase Inhibitors
Kinases are the major anticancer drug target class of the 21st century1 with nearly 60 small molecule kinase inhibitors approved for clinical use in the first two decades. Key to the success of kinase inhibitor [...]
Case study: Altered drug response in 3D spheroids
May 25, 2021: A new case study is presented, in which the use of spheroids for the determination of drug sensitivity is highlighted. The figure shows dose-response curves of the KRAS [...]
Case study: Phosphorylation status determines kinase inhibitor binding
April 28, 2021: A new case study is presented going in-depth on the biochemical properties of Bruton’s tyrosine kinase (BTK) inhibitors. The figure shows surface plasmon resonance sensorgrams for the binding [...]
[Webinar] How to Overcome Acquired Resistance Against Kinase Inhibitors
Resistance development is all too common in cancer treatment and leads to cancer cells evading targeted therapies.To better understand how these resistance mechanisms work and in order to help develop new therapies, Investigator Helma Simons–van [...]